Navigation Links
InfoLogix CEO to Address Hidden Value of ID Technology at International Conference
Date:11/12/2008
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:MU research team makes progress toward 'printing' organs 2Health News:MU research team makes progress toward 'printing' organs 3Health News:Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: 2Health News:Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: 3Health News:Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: 4Health News:NBC 'Today' Co-Host Al Roker to Serve as a National Ambassador for Inspired by Diabetes Campaign to Help Children With Diabetes 2Health News:NBC 'Today' Co-Host Al Roker to Serve as a National Ambassador for Inspired by Diabetes Campaign to Help Children With Diabetes 3Health News:NBC 'Today' Co-Host Al Roker to Serve as a National Ambassador for Inspired by Diabetes Campaign to Help Children With Diabetes 4Health News:NBC 'Today' Co-Host Al Roker to Serve as a National Ambassador for Inspired by Diabetes Campaign to Help Children With Diabetes 5Health News:NBC 'Today' Co-Host Al Roker to Serve as a National Ambassador for Inspired by Diabetes Campaign to Help Children With Diabetes 6Health News:'AHF/India Cares' Provides Second-line AIDS Drugs to Activists in India 2Health News:'AHF/India Cares' Provides Second-line AIDS Drugs to Activists in India 3Health News:NIH grant advances dentistry school's work on psychosocial stress 2Health News:NIH grant advances dentistry school's work on psychosocial stress 3Health News:Energy Drinks Could Pose Blood Pressure Risks 2
Breaking Medicine Technology:Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 2Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 3Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 4Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 5Veran Medical Receives FDA Clearance to Market Electromagnetic Navigated Bronchoscopy Product: The SPiN Drive(TM) System 2AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 2AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 3The American Association for Cancer Research Congratulates President Elect on Nobel Prize 58890 1The American Association for Cancer Research Congratulates President Elect on Nobel Prize 58890 2The American Association for Cancer Research Congratulates President Elect on Nobel Prize 58890 3The American Association for Cancer Research Congratulates President Elect on Nobel Prize 58890 4Aurora Health Care Among Six Sites Chosen for National Medicare Collaborative on Geriatric Care 58886 1Aurora Health Care Among Six Sites Chosen for National Medicare Collaborative on Geriatric Care 58886 2Aurora Health Care Among Six Sites Chosen for National Medicare Collaborative on Geriatric Care 58886 3Aurora Health Care Among Six Sites Chosen for National Medicare Collaborative on Geriatric Care 58886 4Federal Stimulus Funding Channels More Than 2440 Million to Fred Hutchinson Cancer Research Center 58882 1Federal Stimulus Funding Channels More Than 2440 Million to Fred Hutchinson Cancer Research Center 58882 2Federal Stimulus Funding Channels More Than 2440 Million to Fred Hutchinson Cancer Research Center 58882 3Federal Stimulus Funding Channels More Than 2440 Million to Fred Hutchinson Cancer Research Center 58882 4
Other Medicine Technology:Ridge Diagnostics, Inc. Awarded Phase 2 National Science Foundation Grant 2Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 2Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 3Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 4Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 5Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 6Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 7Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 8Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 9Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 10Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 11Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 12